Publications by authors named "L Voillat"
J Wrist Surg
October 2024
Article Synopsis
- The study aims to enhance conservative treatment for distal radius and scaphoid fractures by developing patient-specific anatomical braces (PSABs) that improve comfort and fracture stabilization while minimizing cast-related issues.
- A variety of 3D-printed splint prototypes were tested with healthy volunteers to assess comfort and satisfaction, while also comparing the mechanical properties of the final prototype against traditional casts and prefabricated splints.
- The final PSAB prototype showed high satisfaction among users, was lightweight (under 90g), and outperformed conventional methods in terms of stiffness, making it a promising alternative for treating these specific fractures.
Article Synopsis
- The FIRE observational study assessed the effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia (CLL) in France, with a maximum follow-up of five years post-treatment initiation.
- The study included 388 patients and found median progression-free survival (PFS) of approximately 53 months for both retrospective and prospective patients, with no significant difference in PFS for those with or without dose reductions.
- The most common adverse events were infections, with a notable percentage of patients experiencing treatment-emergent adverse events leading to death, though overall effectiveness and safety outcomes aligned with previous studies.
Article Synopsis
- - The phase II trial assessed the effectiveness of the RiBVD treatment (rituximab, bendamustine, velcade, and dexamethasone) in patients over 65 with mantle cell lymphoma (MCL), which resulted in a median progression-free survival of 79 months and overall survival of 111 months.
- - TP53 mutation status and albumin levels were identified as significant prognostic factors, with TP53 mutations linked to a higher risk of shorter progression-free survival and overall survival in the analyzed patient population.
- - A scoring system combining TP53 mutation status and albumin levels allowed differentiation of patient outcomes, indicating varying survival rates based on the presence of these factors, thus enhancing prognostic assessments
Article Synopsis
- Cytogenetic abnormalities are key indicators of prognosis in multiple myeloma, with del(1p32) identified as a significant negative factor after del(17p).
- In a study of 2,551 newly diagnosed patients, those with del(1p32) had a much shorter overall survival (49 months) compared to those without it (124 months).
- The impact of del(1p32) is even worse for patients with biallelic deletions, leading to a median overall survival of just 25 months, emphasizing the need for thorough assessment at diagnosis for appropriate treatment strategies.
